title: Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma.
abstract: Lymphoblastic lymphoma is an aggressive subtype of non-Hodgkin lymphoma. Identification of prognostic factors for these patients, especially for patients with T-cell lymphoblastic lymphoma (T-LBL), remains a challenge. This is largely due to the relative rarity of the disease and lack of adequate samples for biological research. T-LBL is more common in Asia than in Western countries. In an attempt to explore novel prognostic markers for T-LBL, we conducted retrospective study of archived diagnostic specimens from 57 Chinese patients with well-defined diagnosis of T-LBL. Using quantitative real-time reverse transcription-PCR, we analyzed miR-17 and miR-19 expression levels in formalin-fixed and paraffin-embedded lymph node specimens from these patients, together with reactive lymph node controls. We correlated molecular findings to patients' immunophenotype and clinical follow-up information. MYC protein expression was also evaluated in these patients. We found that miR-17 and miR-19 levels were concordant and upregulated in T-LBL in comparison with controls. Statistical analysis showed that higher expression of miR-17 and miR-19, and positive MYC protein results were associated with a shorter overall survival of T-LBL. In addition, miR-17 and miR-19 appeared to be independent prognostic factors for T-LBL. We demonstrate here that upregulation of miR-17 and miR-19 correlates with poor clinical outcome of T-LBL, indicating that miR-17 and miR-19 may be considered as potential unfavorable prognostic markers for T-LBL.
authors.affiliation: Department of Pathology, Shanxi Cancer Hospital and Shanxi Medical University, Taiyuan, Shanxi 030013, China.
authors.forename: Yanfeng
authors.initials: Y
authors.lastname: Xi
authors.affiliation: Department of Pathology, Shanxi Cancer Hospital and Shanxi Medical University, Taiyuan, Shanxi 030013, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: Shanxi Medical University, Taiyuan, Shanxi, 030013, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.affiliation: Department of Pathology, Shanxi Cancer Hospital and Shanxi Medical University, Taiyuan, Shanxi 030013, China.
authors.forename: Wenqi
authors.initials: W
authors.lastname: Bai
authors.affiliation: Department of Pathology, Shanxi Cancer Hospital and Shanxi Medical University, Taiyuan, Shanxi 030013, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Gao
authors.affiliation: Department of Pathology, Shanxi Cancer Hospital and Shanxi Medical University, Taiyuan, Shanxi 030013, China. Electronic address: 326498302@qq.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Bai
authors.affiliation: Shanxi Medical University, Taiyuan, Shanxi, 030013, China.
authors.forename: Yanhua
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Shanxi Medical University, Taiyuan, Shanxi, 030013, China.
authors.forename: Yueqin
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA. Electronic address: yning5@jhmi.edu.
authors.forename: Yi
authors.initials: Y
authors.lastname: Ning
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C524941:MIRN17 microRNA, human; C549214:MIRN19A microRNA, human; D035683:MicroRNAs
keywords: Lymphoma; Prognosis; T-cell; miRNA-17; miRNA-19